While a setback for Seattle Genetics, the failure of lintuzumab was not unexpected given the aggressive nature of AML and the fact that a myriad of drugs aimed at benefiting elderly patients with this form of leukemia have likewise failed to produce a survival benefit. "We're disappointed about the data, but this was the right study, it was executed very well and gave us a clear answer," said Seattle Genetics CEO Clay Siegall, in an interview conducted Sunday afternoon. Seattle Genetics shares closed Friday at $12.72. Most investors who own the stock or follow it have viewed lintuzumab as a long shot. Much more attention is being paid to Seattle Genetics' lead cancer drug, SGN-35, which is expected to have data from two important clinical trials report within six weeks. If positive, Seattle Genetics will be in a position to seek regulatory approval for SGN-35 in the first half of 2011, said Siegall.